Search results
Results from the WOW.Com Content Network
Lomustine is an alkylating chemotherapy drug that is indicated by the FDA for the treatment of patients with brain tumors (primary and metastatic), following any necessary surgery and radiation, as well as for treatment of progressive Hodgkin’s lymphoma. [8]
Ifosfamide is a DNA-damaging alkylating agent, belonging to the same class of chemotherapy drugs as cyclophosphamide. It is a prodrug, meaning that It has to be converted by CYP450 into its main active metabolites-(Iso)phosphoramide mustards. These metabolites form DNA cross links mainly at Guanine N-7 positions. [5]
The BC Cancer Foundation is the beneficiary of major fundraising events. The Workout to Conquer Cancer is a 31-day challenge to move every day in May while fundraising.. The Tour de Cure is an annual cycling event that raises funds for the BC Cancer Foundation to support cancer research and patient care programs.
Description - includes the proprietary name (if any), nonproprietary name, dosage form(s), qualitative and/or quantitative ingredient information, the pharmacologic or therapeutic class of the drug, chemical name and structural formula of the drug, and if appropriate, other important chemical or physical information, such as physical constants ...
This is a list of chemotherapeutic agents, also known as cytotoxic agents or cytostatic drugs, that are known to be of use in chemotherapy for cancer.This list is organized by type of agent, although the subsections are not necessarily definitive and are subject to revision.
With direct links to the cancer centres across the province, discoveries at the Research Centre are quickly translated into clinical applications. In 2005 the Canada Green Building Council certified the building had met LEED ( Leadership in Energy and Environmental Design ) Gold standards for its sustainable design , making it the first health ...
Mesna reduces the toxicity of urotoxic compounds that may form after chemotherapy administration. Mesna is a water-soluble compound with antioxidant properties, and is given concomitantly with the chemotherapeutic agents cyclophosphamide and ifosfamide .
Ling undertook post-doctoral training with Nobel laureate Fred Sanger at Cambridge University before returning to Toronto. [3] He is currently [when?] Assistant Dean of the Faculty of Medicine at the University of British Columbia and former vice-president, Discovery at the BC Cancer Agency in Vancouver, British Columbia, as well as the President and Scientific Director of the Terry Fox ...